AltPep

Exciting news from AltPep today! Carolyn Tallon, Ph,D., one of our Principal Scientists, is presenting data at the 2025 AAIC meeting in Toronto, Canada, demonstrating that AltPep’s custom-designed peptide (SOBIN-AD) for Alzheimer’s disease, increases clearance of Aβ toxic oligomers and inhibits plaque formation. In addition, highly selective targeting in a Tg AD mouse model improved short-term memory and reduced plaque burden. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of Alzheimer’s disease! #Alzheimers #Research #Alzscience https://xmrrwallet.com/cmx.plnkd.in/gug9isQ9

We're #hiring a new Medical Laboratory Scientist in Seattle, Washington. Apply today or share this post with your network.

We're #hiring a new Research Associate - Peptide Production in Seattle, Washington. Apply today or share this post with your network.

We're #hiring a new Senior Research Associate in Seattle, Washington. Apply today or share this post with your network.

Fascinating new data from Valerie Daggett’s lab at University of Washington, recently published in the Journal of Biomedical Materials Research, demonstrates a gauze containing α-sheet peptide inhibits bacteria biofilms. This exciting advance has potential application for wound care by stopping resistant infections and making current antibiotics more effective. As the world faces an increasing threat from antibiotic resistance, and as the development of traditional antibiotics declines, there is a tremendous need for promising new approaches, like this one.   Read the news article from the University of Washington: https://xmrrwallet.com/cmx.plnkd.in/gK4Htx2A Read the journal article: https://xmrrwallet.com/cmx.plnkd.in/gRCXh6_R #research #science #medtech #UW

We're #hiring a new Medical Laboratory Scientist in Seattle, Washington. Apply today or share this post with your network.

We are thrilled to announce the appointment of Alan Colowick M.D., M.P.H. of Matrix Capital Management to AltPep’s Board of Directors! Alan’s deep experience will be invaluable as we continue our clinical development in AD and PD. Welcome Alan! Find the full release on our website! https://xmrrwallet.com/cmx.paltpep.com/press/ #AlzheimersDisease #ParkinsonsDisease #Research

We're #hiring a new Medical Laboratory Scientist in Seattle, Washington. Apply today or share this post with your network.

We're #hiring a new Research Associate - Peptide Production in Seattle, Washington. Apply today or share this post with your network.

AltPep will be in San Francisco during #JPM25. Reach out if you would like to learn about AltPep’s novel target in amyloid diseases: toxic oligomers. We are developing therapeutic and diagnostic candidates for Alzheimer’s and Parkinson’s based on this target, with AD clinical trials to start next year. For our colleagues conducting AD clinical trials, our diagnostic could also be of interest to test and monitor toxic oligomers in patient plasma samples. Reach out to the team to learn more Denis Sirringhaus #AlzheimersDisease #Research #ParkinsonsDisease